30.71
30.71 (0%)
As of Feb 14, 2025
Tg Therapeutics, Inc. [TGTX]
Source:
Company Overview
TG Therapeutics is a fully-integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell mediated diseases.
| Country | United States |
| Headquarters | new york, new york |
| Phone Number | (212) 554-4484 |
| Industry | manufacturing |
| CEO | Michael S. Weiss |
| Website | tgtherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $329 |
| Operating Profit | $41.9 |
| Net Income | $23.4 |
| Net Cash | $87 |
Profit Ratios
| Gross Margin | $290.5 |
| Operating Margin | 12.7 |
| Profit as % of Revenues | 1,242.4% |
| Profit as % of Assets | 5.2% |
| Profit as % of Stockholder Equity | 10.5% |
Management Effectiveness
| Return on Equity | 10.5% |
| Return on Assets | 4.1% |
| Turnover Ratio | 72.5% |
| EBITA | $41.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $577.7 |
| Total Liabilities | $355.3 |
| Operating Cash Flow | $-40.5 |
| Investing Cash Flow | $-1 |
| Financing Cash Flow | $128.5 |
